 SAN DIEGO, Feb. 11, 2021 GLOBE NEWSWIRE -- Travere Therapeutics, Inc. Nasdaq: TVTX today announced the pricing of an underwritten public offering of 6,550,000 shares of its common stock at a price to the public of 26.75 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be approximately 175.2 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on February 17, 2021, subject to customary closing conditions. In addition, Travere has granted the underwriters for the offering a 30-day option to purchase up to an additional 982,500 shares of its common stock at the public offering price, less the underwriting discounts and commissions. 